Objective To investigate the expression of Cripto-1 in pancreatic cancer and to analyze its clinical significance. Methods Cripto-1 expression in normal pancreas, pancreatic cancer and adjacent non-tumor tissues, chronic pancreatitis tissues and other related tissues was evaluated using immunohistochemistry. The association of Cripto-1 expression with the clinicopathological characteristics and the prognostic value of Cripto-1 in patients with pancreatic cancer were analyzed. Results The expression of Cripto-1 was higher in chronic pancreatitis tissues, pancreatic cancer and its metastases than in normal pancreas (P =0.019, P = 0. 025, and P = 0. 018, respectively). Cripto-1 overexpression was correlated with poorly differentiated pancreatic cancer. The patients with Cripto-1 upregulation had shorter median survival time (8 months vs. 16 months, χ2 = 4. 787, P =0. 029). However, multivariate analysis failed to demonstrate overexpression of Cripto-1 an independent prognostic indicator in patients with pancreatic cancer (HR = 1. 341, 95% CI = 0. 800 -2. 248, P = 0. 266). Conclusions Cripto-1 may play an important role in the development and progression of pancreatic cancer. It can be a potential prognostic biomarker for patients with pancreatic cancer.
All Science Journal Classification (ASJC) codes